Dr. Cojocaru stated, “As with all of our discovery methodologies, or platforms, the two methodologies being presented today rely on our underlying and continuously growing predictive discovery infrastructure. The first discovery platform was created for the prediction of novel cancer targets, including drug resistant and advanced stage cancer. This methodology relies in large part on query algorithms focused on the integrated statistical analysis of both expression and clinical data within the infrastructure and has resulted to date in multiple discoveries, such as the previously disclosed CGEN-928 with potential use for late stage, aggressive and drug resistant multiple myeloma and Rituximab resistant non-Hodgkin’s lymphoma.
Dr. Cojocaru continued, “The second platform was developed to predict targets specifically for the use of monoclonal antibodies in cancer immunotherapy, and is based on a more general Compugen platform for identifying novel members of protein families of high industry interest. Since most traditional approaches for identifying novel members of known protein families are largely based on sequence homology or function, the set of query algorithms for this platform was designed to first discover other types of characteristics shared between known members of the family of interest. Based on this, we select proteins from our discovery infrastructure that share these characteristics and therefore could potentially be unknown family members.”
Dr. Cojocaru continued, “The protein family on which we focused the second platform was the B7/CD28 family, since known members of this family are of high industry interest, have low sequence homology, and have been shown to be appropriate targets for cancer immunotherapy. Our efforts to date with this platform have been very successful, significantly adding to the number of B7/CD28-like proteins previously known. Included in these Compugen discovered molecules are the previously disclosed CGEN-15001T, and also CGEN-15022 and CGEN-15092 which are being disclosed today. CGEN-15022 and CGEN-15092 are the membrane proteins related to the previously disclosed soluble Fc proteins for autoimmune disease, CGEN-15021 and CGEN-15091, respectively. Based on earlier experimental results relating to CGEN-15022 and CGEN-15092, both of which are in our Pipeline Program, these molecules appear to be very promising targets for cancer mAb based therapy and were recently selected by Compugen to be advanced to the mAb development stage.”
Dr. Cojocaru continued, “As previously stated, our ability to rapidly create multiple discovery methodologies in areas of high industry interest rests on our unique and proprietary discovery infrastructure incorporating predictive understandings of numerous biological phenomena at the molecular level.These predictive understandings were accomplished during a decade long and on-going pioneering research effort by Compugen’s scientists and are based on sophisticated analysis of huge amounts of data of various types, such as genetic, molecular, structural, clinical, biological pathways and others. A key aspect of this effort was the development of algorithmic building blocks and other proprietary techniques for the accurate integration of this enormous amount and diverse data. This has resulted in our proven ability to utilize our discovery infrastructure to provide output in the form of meaningful biological information, in addition to continuing enhancement of the infrastructure itself.”
Dr. Cojocaru continued, “As demonstrated by the two methodologies being presented today, a critical component of our infrastructure, which is different for each therapeutic or diagnostic need directed methodology, is development of a set of query algorithms designed for the identification of molecules predicted to address that specific need. Following these infrastructure based activities, all of which are performed totally by computer, the predicted product candidates for the clinical need of interest are validated utilizing well-accepted laboratory experimental procedures. In addition to providing validation of the predicted candidates, these experimental results provide key information for further refining the query algorithms and other aspects of the infrastructure.”
Dr. Cojocaru concluded, “It has taken over a decade for Compugen to create the comprehensive infrastructure required for predictive drug discovery.However, based on the substantial inherent advantages of hypothesis driven research and our excellent results to date, we look forward to both the continuing development and commercialization of our existing discoveries, and an increasing number of attractive product candidates within our focus areas of oncology and immunology”.
Compugen is a leading therapeutic product discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology, either for Compugen or its partners. Unlike traditional high throughput trial and error experimental based drug candidate discovery, Compugen’s discovery efforts are based on systematic and continuously improving in silico (by computer) product candidate prediction and selection followed by experimental validation, with selected product candidates being advanced in its Pipeline Program to the pre-IND stage. Compugen’s in silico predictive models utilize a broad and continuously growing infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities. The Company’s business model primarily involves collaborations covering the further development and commercialization of Compugen-discovered product candidates and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. In 2002, Compugen established an affiliate, Evogene Ltd. (www.evogene.com) (TASE: EVGN.TA), to utilize certain of the Company’s in silico predictive discovery capabilities in agricultural biotechnology. For additional information, please visit Compugen’s corporate website at www.cgen.com.
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as “may”, “expects”, “anticipates”, “believes”, and “intends”, and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are discussed in the “Risk Factors” section Compugen’s Annual Report on Form 20-F for the year ended December 31, 2010 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Compugen’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.
Tsipi HaitovskyGlobal Media Liaison